We are live on ! Find out more
CC

Checkpoint Capital Portfolio holdings

AUM $279M
1-Year Est. Return 45.74%
This Fund
S&P 500
This Quarter Est. Return
-1.4%
1 Year Est. Return
+45.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$166M
AUM Growth
+$16.3M
Cap. Flow
+$18.9M
Cap. Flow %
11.4%
Top 10 Hldgs %
95.06%
Holding
21
New
4
Increased
8
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$11.7M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$7.12M
3
PHAT icon
Phathom Pharmaceuticals
PHAT
+$4.43M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$3.86M
5
PLRX icon
Pliant Therapeutics
PLRX
+$2.99M

Top Sells

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$9.1M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$5.39M
3
VSTM icon
Verastem
VSTM
+$1.99M
4
GHRS icon
GH Research
GHRS
+$1.98M
5
CORT icon
Corcept Therapeutics
CORT
+$795K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
1
Rhythm Pharmaceuticals
RYTM
$7.96B
$37.9M 22.82%
922,100
+96,600
+12% +$3.86M
ARGX icon
2
argenx
ARGX
$54.1B
$35.3M 21.3%
82,150
+150
+0.2% +$57.4K
AXSM icon
3
Axsome Therapeutics
AXSM
$10.9B
$23.4M 14.11%
290,772
+158,335
+120% +$11.7M
AVDL
4
DELISTED
Avadel Pharmaceuticals
AVDL
$16M 9.65%
1,138,178
+436,791
+62% +$7.12M
PTGX icon
5
Protagonist Therapeutics
PTGX
$9.44B
$12.3M 7.42%
355,000
+74,699
+27% +$2.19M
CYTK icon
6
Cytokinetics
CYTK
$10.4B
$10.3M 6.21%
190,000
– –
PHAT icon
7
Phathom Pharmaceuticals
PHAT
$692M
$9.01M 5.43%
875,000
+429,839
+97% +$4.43M
CORT icon
8
Corcept Therapeutics
CORT
$12B
$7.95M 4.79%
244,750
-29,026
-11% -$795K
ATYR
9
aTyr Pharma
ATYR
$50.1M
$3.04M 1.83%
1,946,477
+500,000
+35% +$870K
PLRX icon
10
Pliant Therapeutics
PLRX
$65M
$2.5M 1.5%
+232,200
New +$2.99M
KYMR icon
11
Kymera Therapeutics
KYMR
$8.94B
$2.45M 1.48%
+82,000
New +$2.84M
CDTX
12
DELISTED
Cidara Therapeutics
CDTX
$1.74M 1.05%
+145,417
New +$1.99M
TRVI icon
13
Trevi Therapeutics
TRVI
$2.64B
$1.49M 0.9%
500,089
-5,993
-1% -$16.7K
APLT
14
DELISTED
Applied Therapeutics
APLT
$1.06M 0.64%
227,470
+7,470
+3% +$35.3K
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
$804K 0.48%
+19,695
New +$835K
ALLK
16
DELISTED
Allakos
ALLK
$650K 0.39%
649,957
-118,007
-15% -$140K
ATRA icon
17
Atara Biotherapeutics
ATRA
$76.1M
– –
-35,714
Closed -$620K
GHRS icon
18
GH Research
GHRS
$2.08B
– –
-185,653
Closed -$1.98M
IRWD icon
19
Ironwood Pharmaceuticals
IRWD
$714M
– –
-618,528
Closed -$5.39M
MIRM icon
20
Mirum Pharmaceuticals
MIRM
$6.14B
– –
-362,193
Closed -$9.1M
VSTM icon
21
Verastem
VSTM
$610M
– –
-168,739
Closed -$1.99M

Similar funds

CB
Centennial Bank Conway, Arkansas $279M AUM 20.11% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $278M AUM 14.53% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
BWG
Balanced Wealth Group Westlake, Ohio $279M AUM 17.49% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Checkpoint Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Checkpoint Capital held 21 positions worth $166M, up 11% from $150M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Checkpoint Capital deployed $18.9M of net new capital in Q2 2024, opening 4 new positions and adding to 8 existing holdings. Its largest new stake was Pliant Therapeutics: 232,200 shares worth $2.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Corcept Therapeutics, an estimated $795K trimmed.

  • Checkpoint Capital's largest Q2 2024 buy was Pliant Therapeutics: 232,200 shares worth $2.5M.
  • Checkpoint Capital added most to Axsome Therapeutics in Q2 2024, an estimated $11.7M increase.
  • Checkpoint Capital's biggest Q2 2024 reduction was Corcept Therapeutics, cutting an estimated $795K.
  • Checkpoint Capital fully exited Mirum Pharmaceuticals in Q2 2024, selling an estimated $9.1M.
  • Checkpoint Capital's ten largest holdings make up 95% of its $166M portfolio in Q2 2024.
  • Checkpoint Capital opened 4 new positions and closed 5 in Q2 2024.
  • Checkpoint Capital's portfolio value rose 11% quarter-over-quarter to $166M.

Based on Checkpoint Capital's 13F filing for Q2 2024, filed 14 Aug 2024.